New York State Teachers Retirement System Sells 29,483 Shares of Edwards Lifesciences Corporation $EW

New York State Teachers Retirement System decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 424,311 shares of the medical research company’s stock after selling 29,483 shares during the period. New York State Teachers Retirement System owned approximately 0.07% of Edwards Lifesciences worth $36,173,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. True Wealth Design LLC grew its holdings in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Hantz Financial Services Inc. grew its holdings in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. Finally, Dorato Capital Management acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW opened at $84.08 on Friday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The company has a market capitalization of $48.47 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 2.10 and a beta of 0.95. The business has a 50-day moving average of $82.08 and a 200-day moving average of $82.41.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The firm’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on EW shares. UBS Group reissued a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.